Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation - Quiz - MDSpire

Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation

  • By

  • Sijie Bian

  • Lianhui Zhao

  • Xu Wang

  • Zhangwei Wu

  • Maolin Yang

  • Jianliang Ou

  • Tao Han

  • Faxue Liao

  • Qingkai Xue

  • Xingxing Huo

  • Jun Chang

  • April 27, 2026

  • 0 min

Share

Original Source(s)

Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation

  • by Sijie Bian, Lianhui Zhao, Xu Wang, Zhangwei Wu, Maolin Yang, Jianliang Ou, Tao Han, Faxue Liao, Qingkai Xue, Xingxing Huo, Jun Chang

  • April 27, 2026

Related Content

MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data